2016
Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial
Costa R, Abizaid A, Mehran R, Schofer J, Schuler G, Hauptmann K, Magalhães M, Parise H, Grube E, Investigators B. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovascular Interventions 2016, 9: 51-64. PMID: 26762911, DOI: 10.1016/j.jcin.2015.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDrug-Eluting StentsFemaleGermanyHumansKaplan-Meier EstimateMaleMiddle AgedNeointimaPaclitaxelPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSingle-Blind MethodSirolimusStainless SteelSurface PropertiesTime FactorsTreatment OutcomeConceptsStent late lumen lossPaclitaxel-eluting stentsLate lumen lossDrug-coated stentsStent thrombosisBiolimus A9First-generation paclitaxel-eluting stentsDe novo coronary lesionsMajor adverse cardiac eventsPolymer-free biolimus A9Probable stent thrombosisAdverse cardiac eventsNovo coronary lesionsTarget lesion revascularizationClinical event ratesLong-term outcomesLesion revascularizationAngiographic followCardiac eventsClinical outcomesCoronary lesionsLesions 4Lumen lossStandard doseStainless steel platform
2014
Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Herrmann J, Gersh B, Goldfinger J, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Brener S, Parise H, Fahy M, McAndrew T, Stone G, Mehran R. Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American Journal Of Cardiology 2014, 114: 9-16. PMID: 24846807, DOI: 10.1016/j.amjcard.2014.03.057.Peer-Reviewed Original ResearchConceptsST-segment myocardial infarctionBody mass indexLong-term outcomesHigher body mass indexBMI quartilesMass indexMyocardial infarctionIschemia-driven target vessel revascularizationAcute Myocardial Infarction trialHigher-weight patientsLower cardiac mortalityLowest BMI quartileCardiovascular risk profileMajor bleeding eventsMyocardial Infarction trialTarget vessel revascularizationLong-term mortalityAcute cardiovascular eventsAcute myocardial infarctionLarge multinational cohortBleeding eventsHarmonizing OutcomesHospital mortalityMyocardial reinfarctionNoncardiac mortality
2013
Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures
Dahlen J, Price M, Parise H, Gurbel P. Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. Thrombosis And Haemostasis 2013, 109: 808-816. PMID: 23254993, DOI: 10.1160/th12-08-0608.Peer-Reviewed Original ResearchConceptsPlatelet function testingFunction testingClinical usefulnessP2Y12 inhibitorsPharmacodynamic effectsPredictive valueFuture thrombotic eventsRate of thrombosisManagement of patientsPlatelet function testsNet reclassification improvementDiagnostic performance indicatorsPlatelet P2Y12 receptorPositive predictive valueDiagnostic performance measuresCardiovascular eventsHazard ratioThrombotic eventsRisk stratificationFunction testsPrognostic utilityAntiplatelet effectReclassification improvementRisk factorsP2Y12 receptor
2005
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
Wilson P, D’Agostino R, Parise H, Sullivan L, Meigs J. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation 2005, 112: 3066-3072. PMID: 16275870, DOI: 10.1161/circulationaha.105.539528.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseMetabolic syndromeCardiovascular diseaseRelative riskAge-adjusted relative riskType 2 diabetes mellitusPopulation attributable risk estimatesNew cardiovascular diseaseMetabolic syndrome traitsMiddle-aged adultsDiabetes mellitusIncident casesHeart diseaseNew T2DMT2DMType 2SyndromeEvent ratesRisk estimatesDiseaseSyndrome traitsMellitusWomenMenRisk